Neurocrine Biosciences, Inc.

NASDAQ:NBIX

122.25 (USD) • At close September 13, 2024
Bedrijfsnaam Neurocrine Biosciences, Inc.
Symbool NBIX
Munteenheid USD
Prijs 122.25
Beurswaarde 12,344,316,000
Dividendpercentage 0%
52-weken bereik 103.63 - 157.98
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Dr. Kevin C. Gorman Ph.D.
Website https://www.neurocrine.com

An error occurred while fetching data.

Over Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive

Vergelijkbare Aandelen

DENTSPLY SIRONA Inc. logo

DENTSPLY SIRONA Inc.

XRAY

26.28 USD

Repligen Corporation logo

Repligen Corporation

RGEN

139.99 USD

Exact Sciences Corporation logo

Exact Sciences Corporation

EXAS

65.54 USD

Bruker Corporation logo

Bruker Corporation

BRKR

65.66 USD

Maravai LifeSciences Holdings, Inc. logo

Maravai LifeSciences Holdings, Inc.

MRVI

8.39 USD

NovoCure Limited logo

NovoCure Limited

NVCR

18.57 USD

Masimo Corporation logo

Masimo Corporation

MASI

112.8 USD

Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc

JAZZ

108.79 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)